FY2024 EPS Estimates for Moderna Lowered by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Brookline Capital Management cut their FY2024 earnings per share (EPS) estimates for Moderna in a research note issued on Monday, January 13th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($9.15) per share for the year, down from their previous estimate of ($9.12). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Brookline Capital Management also issued estimates for Moderna’s Q4 2024 earnings at ($2.85) EPS, FY2025 earnings at ($8.56) EPS, FY2026 earnings at ($2.00) EPS, FY2027 earnings at $1.30 EPS and FY2028 earnings at $5.31 EPS.

A number of other analysts have also recently commented on MRNA. Jefferies Financial Group dropped their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Barclays reduced their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Morgan Stanley reduced their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a report on Wednesday. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $76.68.

Moderna Price Performance

NASDAQ MRNA opened at $34.77 on Thursday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $41.44 and its two-hundred day simple moving average is $67.56. Moderna has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the firm earned ($1.39) EPS. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 2,664 shares of company stock valued at $115,210 over the last 90 days. Insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Several hedge funds have recently added to or reduced their stakes in the business. Axiom Advisory LLC grew its stake in shares of Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after buying an additional 198 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in Moderna during the 2nd quarter worth approximately $26,000. Arkadios Wealth Advisors grew its position in Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after acquiring an additional 243 shares during the last quarter. Knuff & Co LLC lifted its position in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares during the last quarter. Finally, Stephens Inc. AR boosted its stake in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after purchasing an additional 245 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.